SAN JOSE, CA / ACCESS Newswire / April 3, 2026 / Avidbank Holdings, Inc. (NASDAQ:AVBH) (“Avidbank Holdings”) announced today that it will release first quarter 2026 earnings results on Monday, April 27, 2026, after the market closes. Upon release, investors may access a copy of the earnings results on the Avidbank website at www.avidbank.com under About Us, Investor Relations.
Avidbank Holdings will host a conference call on Tuesday, April 28, 2026, at 11:00 a.m. (EDT) / 8:00 a.m. (PDT) to discuss its first quarter 2026 results. Investors may call in by dialing (800) 715-9871 within the US and +1(646) 307-1963 for all other locations. The conference ID number is 1715743. Participants may also pre-register for the conference by navigating to https://events.q4inc.com/attendee/983702195.
Alternatively, individuals may listen to a live webcast of the presentation by visiting the link on Avidbank’s website at www.avidbank.com under About Us, Investor Relations. An audio replay of the live webcast is expected to be available by the evening of April 28, 2026, through the Investor Relations section of Avidbank’s website.
About Avidbank
Avidbank Holdings, Inc. (NASDAQ:AVBH), headquartered in San Jose, California, offers innovative financial solutions and services. We specialize in commercial & industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, fund finance, and real estate construction and commercial real estate lending. Avidbank provides a different approach to banking. We do what we say.
Contact:
Patrick T. Oakes
Executive Vice President and Chief Financial Officer
408-200-7390
IR@avidbank.com
SOURCE: Avidbank Holdings, Inc.
View the original press release on ACCESS Newswire
IIG's constructed, owned-and-operated northern corridor is attracting strong customer demand, with further expansion already under…
As of the 2025 filing season, the IRS is applying First-Time Abatement automatically - without…
WASHINGTON, DC / ACCESS Newswire / June 8, 2026 / AGS Health®, a leading provider…
Proof-of-concept SHEPHERD study will assess SUL-238's effects on mitochondrial function in patients with Parkinson's disease.…
FAIRFIELD, NJ / ACCESS Newswire / June 8, 2026 / Jerash Holdings (US), Inc. (Nasdaq:JRSH),…
Building the Olfactory Layer of Physical AIHighlighting Progress Across Semiconductor Manufacturing, Healthcare Infrastructure and Physical…